Timapiprant: Completed Phase III enrollment

Eleventa and Oxagen announced the completion of enrollment of 212 patients in a double-blind, placebo-controlled, Russian Phase III trial evaluating 50 mg oral timapiprant once daily for 12 weeks. Ato...